|
Established in 2013, April Bio is a new antibody drug company that develops global innovative new drugs in a variety of therapeutic areas using its proprietary human antibody library (HuDVFab) technology and SAFA, a sustained platform technology that can increase the half-life of antibody fragment utilization.
Autoimmune disease treatment (CD40L target) APB-A1, preclinical inflammatory autoimmune disease treatment (IL-18 target) APB-R3, male infertility treatment (FSH target) APB-R2, etc. Is developing.
Recently, April Bio decided to issue a paid-in capital increase of 10 billion won worth to a third party for Yuhan Corporation. In 2020, it attracted 18 billion won worth of Series B investment, and at this time Yuhan Corporation as a strategic investor (SI) invested 3 billion won in April Bio to acquire a 4.89% stake. Since then, Yuhan Corporation and April Bio signed a business agreement for joint research and new drug development, strengthening research cooperation, and strengthening the partnership through additional investment.
Yuhan explained, “The reason for making additional investment is to further accelerate joint research using it in the future as the excellence of SAFA, an independent platform technology owned by April Bio, is recognized.”
Meanwhile, April Bio is preparing for a special listing on the KOSDAQ market this year through technology evaluation, and major financial investors are LB Investment, TS Investment, Hana Financial Investment, Ebest Investment & Securities, SJ Investment Partners, Daekyo Investment, Mirae Equity Partners, These include SM Cino Technology Investment, BSK Investment, Wooshin Venture Investment, and Kolon Investment.